All News
Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M
Dr. Rachel Tate uptoTate ( View Tweet)
Rilonacept may have a role in Tx of steroid-refractory recurrent idiopathic pericarditis abstr#2905 #ACR19 #cleclinicrheum @RheumNow @CleClinicMD
Cassandra Calabrese CCalabreseDO ( View Tweet)
Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd
#ACR19 @RheumNow abs#2877
Dr. Rachel Tate uptoTate ( View Tweet)
Infections In out patients are increased as measured by antimicromial scripts with RA and TNFi use comparing popn controls and pre and post RA TNFi use in pan Iceland registry #ACR19 #ACR @RheumNow abstr 2873. Higher than controls pre &even more after TNFi https://t.co/SlkIPP9WsJ
Janet Pope Janetbirdope ( View Tweet)
A new MBDA-based CVD risk score looks promising, for accurately predicting CVD risk in RA pts, abstr#2350 @RheumNow #ACR19
Cassandra Calabrese CCalabreseDO ( View Tweet)
Do you think of cachexia in SLE? I didn't before this. Maybe I missed what it is as 50% of Hopkins lupus cohort have cachexia by 5 yrs. Mot my experience #ACR #ACR19 @RheumNow #SLE abstract 1567 https://t.co/7cAU9r7RJV
Janet Pope Janetbirdope ( View Tweet)
Continue or stop biologics for RA if pregnant? Abstr# 2292 and 2279 show increase in flares, GC use, if biologics stopped at time of positive pregnancy test @RheumNow #ACR19
Cassandra Calabrese CCalabreseDO ( View Tweet)
Icelandic study shows RA pts use more antimicrobials in the 2 yrs prior to TNFi tx and have increased use 2 yrs after tx. https://t.co/GyUdQT2NvD abs#2873 #ACR19 @RheumNow https://t.co/HKU2IOPwcw
Dr. Rachel Tate uptoTate ( View Tweet)
Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR19 @RheumNow abstr 2874 https://t.co/pLVAkQ7UR6
Janet Pope Janetbirdope ( View Tweet)
Quote of the day “The absence of crackles is not the absence of ILD in systemic sclerosis” by Saketkoo LA in SSc. Also think of other causes of dyspnoea and cough in SSc #ACR19 @RheumNow https://t.co/po2XG9hnYY
Dr. Antoni Chan synovialjoints ( View Tweet)
RA patients failing either UPA or adalimumab may benefit from switching to the other therapy abstr#2907 #ACR19 @RheumNow
Cassandra Calabrese CCalabreseDO ( View Tweet)
Go-DACT proof on concept results: golimumab + MTX superior to monotherapy MTX in PsA dactylitis. https://t.co/dEGnjiuGZf #ACR19 @RheumNow abs#2876
Dr. Rachel Tate uptoTate ( View Tweet)
Can paired synovial MCP biopsies in ERA predict damage? Nice study shows Bcell rich biopsy that is perstistent. This may eventually help with Rx and prognosis #ACR19 #ACR @RheumNow abstract 2870 https://t.co/oQTgiTOtEX
Janet Pope Janetbirdope ( View Tweet)
#ACR19 Abst#2877: Open Label Extension of a Phase 2 for risankizumab (IL23i) for PsA
Effect seems to stick around and favorable safety profile
@RheumNow https://t.co/pFn0q61exs
Mike Putman EBRheum ( View Tweet)
Mortality in joint replacements in RA vs OA at 30 days #ACR19 #ACR @RheumNow Abstract 2872. RA more readmission 2 x higher and increased mortality https://t.co/XjlpzZPUNl
Janet Pope Janetbirdope ( View Tweet)
Early RA is getting better over time periods but maybe just ACPA positive for sustained drug free remission. Counter intuitive. But still more in ACPA beg but less improvement Interesting. #ACR #ACR19 @RheumNow abstract 2871 https://t.co/JQJ90wxksi
Janet Pope Janetbirdope ( View Tweet)
Treatment approach for skin disease in systemic sclerosis SSc from Hummers L. Polymerase 3 antibody predictive of skin progression and MMF benecial for treating SSc skin disease #ACR19 @RheumNow https://t.co/rdHOS9S23u
Dr. Antoni Chan synovialjoints ( View Tweet)
#ACR19 Abst#2878 #ACRbest - Tildrakizumab (IL23i) RCT
Good ACR20 (80% v 51%, NNT ~3) regardless of dose; great safety profile. Curiously high PLBO response, expectation bias?
PASI75 phenomenal per usual (80% v 17% plbo, NNT 1-2)
Need IL23/IL17/TNF comparative study!
@RheumNow https://t.co/uEGvsD8KVb
Mike Putman EBRheum ( View Tweet)
#ACR19 Guidelines for OA: my take home is this truly astonishing funnel plot
Virtually zero small negative studies and dozens of small positive studies
Clear trend toward NO effect w/more precision in trial
Publication bias et al. in action!! @RheumNow https://t.co/65nKzghobz
Mike Putman EBRheum ( View Tweet)
@RheumNow #acr19 abs2876 GODACT ph3 trial: glimumab+MTX improves clinical& MRI dactylitis scores better than MTX mono. mean MTX dose in the golimumab+ MTX group 16.3mg/wk & 19.2mg/wk in the MTX mono group . Also better DAS28,DAPSA,PASDAS& tNAPSI at wk 24 in golimumab group
Olga Petryna DrPetryna ( View Tweet)